# Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

> **NCT06690216** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Man Hu** · enrollment: 100 (estimated)

## Conditions studied

- Glioblastoma (GBM)
- Head and Neck Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
- Esophageal Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PET/CT （[18F]AlF-NOTA-PCP2）
- **DIAGNOSTIC_TEST:** [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors

## Key facts

- **NCT ID:** NCT06690216
- **Lead sponsor:** Man Hu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-03-30
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690216, "Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06690216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*